Survival Outcomes among Human Epidermal Growth Factor Receptor 2- (HER2-) Positive Breast Cancer Patients at Kenyatta National Hospital

Table 4

Mean survival time estimates among HER2-positive breast cancer patients.

Variable	(95% CI)	Log-rank test ( value)
Early-stage curable disease
Age (in years)		0.556
<60 years	(38.4-49.9)
≥60 years	(19.6-54.3)
Comorbidity		0.150
Present	(30.2-46.8)
Absent	(39.1-53.9)
Tumor response		0.165
Complete response	(54.0-60.9)
Partial response	(47.9-50.9)
Nonresponse	(29.3-52.6)
Progression of the disease	(27.8-50.9)
Diabetes mellitus		0.032
No	(39.5-51.7)
Yes	(19.0-45.9)
Metastatic disease
Age (in years)
<60 years	(6.3-11.3)	0.921
≥60 years	(8.3-10.2)
Comorbidity
Present	(7.2-10.7)	0.840
Absent	(6.3-11.9)
Tumor response
Nonresponse	(6.0-9.9)	0.453
Progression of the disease	(7.4-11.1)
Diabetes mellitus
No	(7.3-11.5)	0.506
Yes	(5.5-10.9)

Statistically significant value <0.05.